News | Implantable Cardiac Monitor (ICM) | March 14, 2017

Heart Monitoring Technology Reveals Risks for Climbers at High Altitudes

Findings reveal 50 percent of the subjects experienced significant pauses in their heartbeat over the course of 51 days

heart monitoring technology, climbers, high altitudes, Circulation study, cardiac diagnostics, Medtronic, Reveal LINQ

March 14, 2017 — Climbing above 4,000 meters can provoke abnormal heart rhythms in otherwise healthy mountaineers, with the abnormalities increasing with altitude, new research has shown.

The study, by sports scientists at Leeds Beckett University (U.K.) and cardiologists at Poole Hospital, found that in a team of 16 healthy mountaineers without a previous history of heart disease, more than half (56.3 percent) experienced rhythm disturbances at altitudes of 4,100 meters or above.

These were either significant pauses in their heartbeat — where the heart stops for three seconds or more — or very fast or irregular heartbeats. The pauses generally took place at night, while the climbers were asleep. All identified abnormalities disappeared once climbers descended below 4,100 meters.

The research, published in the journal Circulation, was carried out with a team of military volunteers from the Defence Medical Services during an expedition to climb Nepal’s Mount Dhaulagiri, in the Himalayas.

The research is the first to continually monitor climbers’ heartbeat over an extended period and shows the potential for such technologies to help with medical diagnoses in remote locations.

The group was studied over a period of at least four months, both before, during and after the 51-day expedition, using implantable cardiac monitors, called Reveal LINQ. Similar in size to a AAA battery the devices were developed by Medtronic. They are typically used in clinical care to detect rare cardiac events but had not previously been tried at high altitude.

Heart rate and activity data were continuously recorded by the device and could be uploaded to a remote stored server by a cellular signal or manually for analysis. The climbers could also trigger the device to specifically store extended recordings of their heartbeat if they experienced any concerning symptoms, such as severe palpitations, which was observed among half the participants. Additional data on the climbers’ blood oxygen levels and physical condition were also collected.

The most commonly identified cardiac abnormality were significant pauses, which were recorded on 81 occasions and affected 50 percent of the subjects. Both the frequency and duration of the pauses increased the higher the climbers went, with the longest pause lasting seven seconds. One climber experienced an episode of a sustained symptomatic irregular fast heartbeat known as atrial fibrillation that lasted for nearly five hours and had kept him awake at night, and another developed a fast abnormal heart rhythm know as a supraventricular tachycardia (SVT) lasting 31 seconds while he attempted to lift a heavy load.

Chris Boos, M.D., visiting professor at Leeds Beckett University and consultant cardiologist at Poole Hospital, who led this study explained: “Our research has delivered a unique and fascinating insight into cardiac physiology at high altitude, showing what happens to the heart rate and rhythm while you sleep and exercise at very high altitude.

“For the majority of mountaineers, there should be no cause for concern, as the pauses during sleep may simply represent normal physiological adaptation to the significant challenges of the very high altitude environment. However, going above 4,000 meters could potentially exacerbate any pre-existing conditions which climbers may or may not already be aware of, and this should be taken into account when planning expeditions.”

He added: “Our study also shows the potential of this kind of technology for delivering medical diagnoses to people in extremely remote locations.”

The team plans to continue its investigations with larger groups of subjects and using even more recent advances in cardiac non-invasive monitoring technology, which will enable even greater detail to be recorded without the need for devices to be implanted.

For more information: www.circ.ahajournals.org

Related Content

Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT)| March 23, 2017
March 23, 2017 — Biotronik announced the launch of the Edora series, its smallest series of...
rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies| March 23, 2017
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low do
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals| March 22, 2017
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of...
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers| March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies
Feature | ACC| March 22, 2017
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presente
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
iFR, iFR vs. FFR, ACC late breaking trial, iFR-SWEDEHEART, DEFINE-FLAIR, Justin E. Davies,

Matthias Götberg, principal investigator for the iFR-SWEDEHEART study, and Justin E. Davies, lead investigator for the DEFINE-FLAIR trial, share key points of their study with DAIC editor Dave Fornell at ACC.17. The trials showed iFR is equal in outcomes to FFR in assessing coronary lesions. 

Feature | FFR Catheters| March 20, 2017
March 20, 2017 — For patients experiencing angina (chest pain) or a heart attack, instantaneous wave-free ratio (iFR)
Overlay Init